No PFS benefit in advanced disease with addition of atezolizumab to chemo, bevacizumab.
By Charles Bankhead
An immunotherapy boost failed to improve outcomes in newly diagnosed advanced ovarian cancer compared with chemotherapy and bevacizumab (Avastin), a large international trial showed.… Read more
By Hannah Slater
The recommendations were based on a review of 17 clinical trials, FDA approvals, and consensus where evidence was lacking.
The American Society for Clinical Oncology (ASCO) published new guidelines on the use of PARP inhibitors in the … Read more
The combination use of niraparib plus bevacizumab significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer.
The combination use of niraparib (Zejula) plus bevacizumab (Avastin) significantly improved clinical outcomes, compared with niraparib … Read more
NEW YORK – The US Food and Drug Administration has approved olaparib (AstraZeneca/Merck’s Lynparza) in combination with bevacizumab (Genentech’s Avastin) as a maintenance regimen for advanced ovarian cancer patients who have homologous recombination deficiency (HRD) and are responding to first-line … Read more
By Beth Fand Incollingo
The Food and Drug Administration (FDA) has approved the combination of two targeted drugs, Lynparza (olaparib) and Avastin (bevacizumab), for patients with advanced ovarian cancer who have responded to initial treatment with platinum-based chemotherapy plus Avastin … Read more
By Pam Harrison
Replacing gemcitabine (Gemzar) with pegylated liposomal doxorubicin in a standard platinum-based regimen improved survival in recurrent ovarian cancer, a phase III trial has shown.
In a cohort of nearly 700 women receiving carboplatin plus bevacizumab (Avastin), median … Read more
By Gina Columbus
Frontline niraparib in addition to bevacizumab as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response to frontline platinum-based chemotherapy with bevacizumab, according to the phase II … Read more
By Gina Columbus
The combination of olaparib (Lynparza) and bevacizumab (Avastin) was found to improve progression-free survival (PFS) outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the … Read more
By Charles Bankhead
Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup.
Dual maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in women with newly diagnosed advanced ovarian cancer, as compared with single-agent bevacizumab, a … Read more
By Dave Levitan
The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. The chemotherapy-free regimen will now be tested in a phase III … Read more
By Ian Ingram
Benefit seen across all subgroups for patients with platinum-sensitive disease.
Ovarian cancer patients with recurrent, platinum-sensitive disease experienced a longer interval without disease progression when bevacizumab (Avastin) was added to niraparib (Zejula), a phase II study found.… Read more
A gynecologic oncologist at the Stephenson Cancer Center at OU Medicine was a national leader of a newly published research study that reveals good news for women with ovarian cancer—longer survival times plus a treatment option that causes fewer difficult … Read more
By Charles Bankhead
No PFS or OS benefit, more toxicity with IP verses IV regimens
Final results of a highly anticipated randomized trial failed to show a survival benefit with intraperitoneal (IP) chemotherapy in patients with newly diagnosed advanced ovarian … Read more
By Ian Ingram
Clinical benefit rate tops 90% in pair of single-center studies.
Two early trials of novel combinations showed promising clinical activity in gynecologic cancers at a late-breaking abstract session at the Society of Gynecologic Oncology (SGO) meeting here.… Read more
By Christina Bennett, MS
Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide showed clinical activity in patients with recurrent epithelial ovarian cancer, according to the results of an open-label phase II trial (LBA4) presented at the 2019 Society of … Read more
A recent study conducted at Denmark’s Vejle Hospital, published in Pharmacological Research, provides evidence of delta-tocotrienol’s benefits for cancer patients. Results of the open-label trial suggest that American River Nutrition-manufactured delta-tocotrienol in combination with bevacizumab had additive effects in chemotherapy … Read more
A new study suggests that a rechallenge with bevacizumab in combination with platinum-based chemotherapy may prolong progression-free survival (PFS) in patients with recurrent ovarian cancer (ROC) who already received this agent during first-line treatment. The study was presented by Italian … Read more
Today, the U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with chemotherapy (carboplatin and paclitaxel) followed by bevacizumab as a single agent for the treatment of women with advanced (stage III or IV) ovarian cancer following initial … Read more
Women with advanced ovarian cancer previously treated with bevacizumab (Avastin) had a 3-month improvement in progression-free survival (PFS) when they received second-line therapy that included bevacizumab, European investigators reported.
Median PFS increased from 8.8 months with platinum-based chemotherapy to 11.8 … Read more
Myriad Genetics and AstraZeneca have expanded their collaboration to conduct a study to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab).
Myriad’s myChoice HRD Plus is a test for BRCA1 … Read more
